Cue Biopharma, Inc.2025财年第一财季实现净利润-12.26百万美元，同比增加0.73%

市场透视2025-05-19

5月19日，Cue Biopharma, Inc.（CUE.US）公布财报，公告显示公司2025财年第一财季净利润为-12.26百万美元，同比增加0.73%；其中营业收入为421000.00美元，同比减少75.52%，每股基本收益为-0.17美元。从资产负债表来看，Cue Biopharma, Inc.（CUE.US）总负债15.67百万美元，其中短期债务6.95百万美元，资产负债比为1.42，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536591747?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536591747","market":"us","top_or_hot":-1,"title":"Cue Biopharma, Inc.2025财年第一财季实现净利润-12.26百万美元，同比增加0.73%","media":"市场透视","content":"<div>\n<p>5月19日，Cue Biopharma, Inc.（CUE.US）公布财报，公告显示公司2025财年第一财季净利润为-12.26百万美元，同比增加0.73%；其中营业收入为421000.00美元，同比减少75.52%，每股基本收益为-0.17美元。从资产负债表来看，Cue Biopharma, Inc.（CUE.US）总负债15.67百万美元，其中短期债务6.95百万美元，资产负债比为1.42，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000347a482f0bc&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cue Biopharma, Inc.2025财年第一财季实现净利润-12.26百万美元，同比增加0.73%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCue Biopharma, Inc.2025财年第一财季实现净利润-12.26百万美元，同比增加0.73%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000347a482f0bc&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Cue Biopharma, Inc.（CUE.US）公布财报，公告显示公司2025财年第一财季净利润为-12.26百万美元，同比增加0.73%；其中营业收入为421000.00美元，同比减少75.52%，每股基本收益为-0.17美元。从资产负债表来看，Cue Biopharma, Inc.（CUE.US）总负债15.67百万美元，其中短期债务6.95百万美元，资产负债比为1.42，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000347a482f0bc&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUE","symbol_name":"Cue Biopharma, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000347a482f0bc&s=b","article_id":"2536591747","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000347a482f0bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536591747","pubTimestamp":1747584065,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Cue Biopharma, Inc.公布财报，公告显示公司2025财年第一财季净利润为-12.26百万美元，同比增加0.73%；其中营业收入为421000.00美元，同比减少75.52%，每股基本收益为-0.17美元。机构评级：截至2025年5月19日，当前有3家机构对Cue Biopharma, Inc.目标价做出预测，其中目标均价为3.33美元，其中最低目标价为2.00美元，最高目标价为6.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CUE":"Cue Biopharma, Inc."},"translate_title":"Cue Biopharma, Inc. achieved net profit of-US $12.26 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 0.73%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUE":1},"content_text":"5月19日，Cue Biopharma, Inc.（CUE.US）公布财报，公告显示公司2025财年第一财季净利润为-12.26百万美元，同比增加0.73%；其中营业收入为421000.00美元，同比减少75.52%，每股基本收益为-0.17美元。从资产负债表来看，Cue Biopharma, Inc.（CUE.US）总负债15.67百万美元，其中短期债务6.95百万美元，资产负债比为1.42，流动比率为1.03。机构评级：截至2025年5月19日，当前有3家机构对Cue Biopharma, Inc.目标价做出预测，其中目标均价为3.33美元，其中最低目标价为2.00美元，最高目标价为6.00美元。公司简介：Cue Biopharma Inc 是一家临床阶段的生物制药公司。该公司正在开发一类新型专有生物制剂药物，用于选择性调节人体免疫系统，以治疗多种癌症和自身免疫性疾病。其目标是通过生物候选药物产品平台为癌症和自身免疫性疾病患者提供显著改善的治疗效果。正在筹备中的其他产品包括 CUE-101 作为单一疗法、CUE-101 Pembrolizumab、CUE-102、CUE-103 等。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536591747","isCrawlerRequest":true}